EULAR 2024 Trials on Medications for Spondyloarthritis

Presentation and analysis of various trials at EULAR 2024 examining the effectiveness and safety of different medications on disease activity, function, and quality of life in patients with non-radiographic axial spondyloarthritis. Insights provided on structural damage progression and the impact of medications such as B. mexisumab and exeKizumab on reducing erosions and achieving clinical remission in patients with spondyloarthritis.